Remarkable Improvement in Clinical Course and Serum KL-6 Levels after Initiation of High-Dose Inhaled Budesonide in Pulmonary Sarcoidosis

YOSHITAKA MORIMATSU; MASAKI OKAMOTO; TOMOTAKA KAWAYAMA; YUSUKE MIZOGUCHI; HARUKI IMAOKA; HIDEO OGINO; TAKETOSHI KAWAZU; TATSUYA ISHITAKE; TOMOAKI HOSHINO

doi:10.2739/kurumemedj.MS661003

この記事には本公開記事があります。本公開記事を参照してください。
引用する場合も本公開記事を引用してください。

Remarkable Improvement in Clinical Course and Serum KL-6 Levels after Initiation of High-Dose Inhaled Budesonide in Pulmonary Sarcoidosis

YOSHITAKA MORIMATSU, MASAKI OKAMOTO, TOMOTAKA KAWAYAMA, YUSUKE MIZOGUCHI, HARUKI IMAOKA, HIDEO OGINO, TAKETOSHI KAWAZU, TATSUYA ISHITAKE, TOMOAKI HOSHINO

著者情報

キーワード: pulmonary sarcoidosis, sarcoidosis-associated interstitial lung disease, KL-6, inhaled corticosteroid, budesonide, alveolar-capillary membrane permeability

ジャーナルフリー早期公開

論文ID: MS661003

DOI https://doi.org/10.2739/kurumemedj.MS661003

この記事には本公開記事があります。

The final version of this article is now available: Vol. 66 (2019), No. 1 pp. 71-75

詳細

抄録

Summary: We present a pulmonary sarcoidosis patient with specific elevation of serum Krebs von den lungen-6 (KL-6) levels, who was successfully treated with inhaled corticosteroids. Pulmonary sarcoidosis was initially identified as a chest radiograph abnormality during a routine medical examination, and subsequently confirmed by a high serum level of soluble interleukin 2 receptor. The patient was started on high-dose inhaled budesonide because of high serum levels of angiotensin-converting enzyme (ACE) and KL-6. Following treatment, radiographic findings improved, ACE levels normalized, and serum KL-6 levels markedly decreased. No recurrence was detected at 100 months with a budesonide dosage of 800 μg/day. This case demonstrates the efficacy of highdose inhaled corticosteroids for the initial treatment of pulmonary sarcoidosis.

責任著者(Corresponding author)

J-STAGEへの登録はこちら（無料）